Does potential longterm risk for leukemia influence your decision for using hydroxyurea in young patients with myeloproliferative neoplasms?   

Thanks for the great question. I think there is a range of passionate options about the matter, which is sure to stir up debate. One can infer by the number of opinions on the topic, the data is limited (where data lacks, opinions abound). So here is my take: It does not influence my decision making...